|
ApoImmune Named 2008 Hot Dozen Company — ENTERPRISECORP recognizes local companies for fast-growth and achievement
December 9, 2008 (Louisville, KY) - ApoImmune, Inc., a biotechnology company developing immunotherapies, has been named a 2008 Hot Dozen company by Greater Louisville Inc.'s (GLI) ENTERPRISECORP. The Hot Dozen is an annual celebration of 12 locally-owned companies who have benefited from Louisville's entrepreneurial atmosphere and continue to thrive in our region. The companies represent innovation and entrepreneurship in Louisville's business community.
Hot Dozen companies are selected because they exemplify Louisville as a place to start and grow a company. Honoring them is part of ENTERPRISECORP's mission to create a new culture of entrepreneurship and dramatically increase the number and quality of fast-growth, entrepreneurial companies headquartered in our region.
"The companies selected for the Hot Dozen contribute to our city's job and wealth creation and with that comes the need to support their talent attraction efforts," said Louisville Mayor Jerry Abramson. "Attracting high quality talent, whether from within our community, from the region or nationally requires our continued focus on world class amenities," he said.
All the Hot Dozen companies will be honored at the Hot Dozen Holiday Showcase at Old National Bank, Preston Pointe on Tuesday, December 9. The event is a celebration of their success and an opportunity for the Hot Dozen companies to network and socialize with other companies and individuals in the entrepreneurial community.
About ENTERPRISECORP
ENTERPRISECORP is the division of Greater Louisville Inc. that specializes in developing the region's fast-growth entrepreneurial sector. ENTERPRISECORP has helped 60 clients secure over $65 Million in financing, and 6 of our clients have experienced $150 Million of liquidity.
About ApoImmune, Inc.
ApoImmune Inc. is a Louisville, Kentucky-based biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. The Company's lead immunotherapy is based on the ProtEx technology's ability to teach the immune system to recognize foreign pathogens as harmful and specifically target those harmful cells for destruction. ApoImmune is also developing ProtEx to suppress the immune system in certain cases, which improves current organ and tissue transplant therapies by protecting the transplant from being attacked by the recipient's immune system when transplanted into the body. An added benefit of the ProtEx immune system suppression technology is that it also reduces the need for powerful immunosuppressive drugs with highly toxic effects that are required after transplantation.
For more information, visit www.apoimmune.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
back to Latest News
|
|
|
